Endocrine Abstracts

Background: The only available SGLT2 inhibitor in Nepal till date is empagliflozin. Empaglilozin has shown to be cardioprotective and renoprotective in randomized trials. It has shown to reduce some weight. There is a lack of data of SGLT2 inhibitors in Nepalese Type 2 diabetes patients.Aim: The aim of our study is to determine the effects of empagliflozin in glycemic control in terms of HbA1C reduction, weight, improvement in eGFR and side effect profil...